Lilly Submits Cymbalta For Chronic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved for fibromyalgia and chronic pain, drug label would include six indications.
You may also be interested in...
Lilly Feels Statistical Pain, Withdraws Cymbalta sNDA
Firm will resubmit the application for chronic pain in 2009 along with a recently completed study using FDA’s preferred analysis for patient drop outs.
Lilly Feels Statistical Pain, Withdraws Cymbalta sNDA
Firm will resubmit the application for chronic pain in 2009 along with a recently completed study using FDA’s preferred analysis for patient drop outs.
Lilly Wins Fibromyalgia Management Indication For Cymbalta
The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.